Congestive heart failure or irregular heart rhythms (arrhythmias) occur in all people with Duchenne muscular dystrophy by age 18. Chest and back deformities (scoliosis). Enlargement of the calf ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

Parent Project Muscular Dystrophy, and whether the drugmaker uses its money to influence, or even muzzle, debate over its Duchenne medicines. It has also bolstered concerns voiced by some parents ...

"Today's approval addresses an urgent unmet medical need and is an important advancement in the treatment of Duchenne muscular dystrophy, a devastating condition with limited treatment options ...

PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy. Life Science Alliance , 2024; 8 (1): e202402831 DOI: 10.26508/lsa.202402831 Cite This Page : ...

A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta Therapeutics said in a statement ...

The approval addressed “an urgent unmet medical need and is an important advancement in the treatment of Duchenne muscular dystrophy, a devastating condition with limited treatment options ...